Can-Fite BioPharma is focused on developing small molecule drugs that target the A3 adenosine receptor (A3AR), which is significantly expressed in inflammatory and cancerous cells while showing low expression in normal cells. This unique expression pattern allows for targeted pharmacological intervention, making A3AR a promising therapeutic target. The company's lead drug candidates, Piclidenoson and Namodenoson, are synthetic agonists that bind with high affinity to A3AR, leading to the modulation of critical signaling pathways such as NF-kB and Wnt. This modulation results in anti-inflammatory and anti-cancer effects, with clinical studies demonstrating an excellent safety profile for these compounds.

In addition to its lead candidates, Can-Fite is also developing CF602, an allosteric modulator that enhances the natural ligand adenosine's affinity for A3AR in areas with elevated adenosine levels, such as in diseased tissues. This approach further emphasizes the company's commitment to targeted therapies that specifically affect pathological cells while sparing normal cells, thereby minimizing potential side effects. The research indicates that A3AR not only serves as a therapeutic target but also as a biological marker, with high receptor expression correlating with improved patient responses to treatment. Overall, Can-Fite's innovative platform leverages the unique properties of A3AR to address significant clinical needs in oncology and inflammatory diseases.

Israel

Can-Fite is an Israel-based biopharmaceutical company that researches and develops small-molecule therapeutics for the treatment of inflammatory, liver, and metabolic diseases.

Can Fite BioPharma (CANFY)

Company Details